Bridget Vazquez, PsyD, breaks down how cancer-related PTSD manifests, why it goes unrecognized, and what patients, caregivers, and clinicians can do.
Advertisement
For millions of patients with cancer, a diagnosis doesn’t just bring a physical battle. It can trigger a trauma response that can linger long after treatment ends, reshaping how people sleep, think, and connect with the world around them.
Bridget Vazquez, PsyD, is a clinical health psychologist at City of Hope, where she works within the Department of Supportive Care Medicine and focuses on improving quality of life for patients, families, and caregivers navigating cancer from diagnosis through survivorship. From this vantage point, she sees what too often gets missed: posttraumatic stress disorder (PTSD) hiding in plain sight, disguised as chemo fatigue, written off as normal worry, or simply never screened for.
In this episode, she breaks down how cancer-related PTSD actually shows up, why it goes unrecognized, and what patients, caregivers, and clinicians can do about it.
Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.